PUBLISHER: Grand View Research | PRODUCT CODE: 1842391
PUBLISHER: Grand View Research | PRODUCT CODE: 1842391
The global preclinical CRO market size was estimated at USD 6.19 billion in 2024 and is projected to reach USD 12.37 billion by 2033, growing at a CAGR of 8.03% from 2025 to 2033. The market is driven escalating R&D investments, the growing complexity of drug development, and the shifting demand toward specialized and advanced therapeutic modalities.
The market is primarily driven by the increasing complexity of drug discovery, along with the high costs of in-house research infrastructure, is driving greater adoption of preclinical CRO services. Drug developers are outsourcing studies such as toxicology, pharmacology, and bioanalysis to specialized service providers to reduce time-to-market and manage operational risks. This trend is further amplified by the growing prevalence of chronic and complex diseases, which require more extensive preclinical evaluations. Outsourcing also enables smaller biotech firms, which often have limited resources, to access advanced technologies and global expertise without the need for large-scale internal setups.
Global Preclinical CRO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preclinical CRO market report based on service, model type, end-use, and region: